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bjectives In an attempt to reduce post-operative events we investigated a new therapeutic strat-
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tely followed by an on-pump coronary artery bypass graft (CABG).
ackground Preventing stroke and cardiovascular events after coronary artery revascularization in
atients with elevated surgical risk is a complex and multifaceted problem.
ethods One hundred-one consecutive patients with severe carotid and coronary artery disease
nd a standard EuroSCORE 5 were included in this multicenter study. Immediately after CAS, pa-
ients underwent CABG. The primary end point was the incidence of stroke, acute myocardial infarc-
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omplications; bleeding and systemic complications within 30 days after treatment; and any stroke,
MI, or death occurring from the 31st day to the end of the 12-month follow-up. All clinical out-
omes were assessed by an independent monitoring board.
esults The rate of procedural success was 98%. The 30-day cumulative incidence of disabling
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Hybrid Carotid-Coronary Revascularization
394he optimal management of patients with concomitant
oronary and carotid artery disease is not known (1– 4).
he importance of this clinical problem is accentuated by
he finding that patients frequently present atherosclero-
is of both arterial systems: 8% to 14% of coronary artery
ypass graft (CABG) patients have significant carotid
rtery stenosis (5), and 40% to 50% of carotid endar-
erectomy (CEA) patients have coronary artery disease
CAD) (6,7).
See page 402
Among patients undergoing CEA in the Veterans Affair
ooperative Study (8) and the ACAS study (Asymptomatic
arotid Atherosclerosis Study) (4), 20% and 49% of deaths,
espectively, were due to cardiac causes. Similarly, the
ncidence of perioperative stroke in patients undergoing
CABG is elevated in those with
concomitant severe carotid ar-
tery stenosis (4).
The combined surgical ap-
proach is associated with an in-
creased risk of mortality and
morbidity (5,9 –11). In the
staged surgical approach that ad-
dresses the carotid artery lesion
with CEA first, followed within
several days to several weeks by
CABG, the incidence of periop-
erative stroke during CABG is
reduced. However, the risk of
acute myocardial infarction
(AMI) during CEA and in the
period preceding CABG is
rather high (5,9,10). Carotid ar-
tery stenting (CAS) with cere-
bral protection devices is rapidly
volving as an alternative to CEA (12), mainly for patients
ith severe carotid artery stenosis at high surgical risk, such
s patients with CAD (13). A staged CAS-CABG ap-
roach has been recently proposed, but the need for a dual
ntiplatelet aggregation therapy lasting 3 to 4 weeks after
tenting might represent a limitation for CABG (14).
We recently proposed a new therapeutic strategy con-
isting of a simultaneous hybrid complete revasculariza-
ion by CAS, immediately followed by on-pump CABG.
uch an approach has the potential to minimize the
ncidence of cardiac events in patients at high surgical
isk (15). In a subsequent larger study we demonstrated
he feasibility of this therapeutic option (16). We carried
ut the prospective SHARP (Simultaneous Hybrid Re-
ascularization by Carotid Artery Stenting and Coronary
bbreviations
nd Acronyms
MI  acute myocardial
nfarction
ABG  coronary artery
ypass graft
AD  coronary artery
isease
AS  carotid artery
tenting
EA  carotid
ndarterectomy
T  computed tomography
uroSCORE  European
ystem for cardiac operative
isk evaluation
IA  transient ischemic
ttackrtery Bypass Grafting) study to demonstrate the poten- mial clinical applicability of this approach as an alternative
o the combined or staged strategies currently adopted.
ethods
he study was conducted in 4 high-volume centers: Tor
ergata University Hospital, Rome, Italy (coordinating
enter); Ospedale Civile di Mirano, Venice, Italy; Heart
enter, Hamburg, Germany; and Clinica San Rocco di
ranciacorta, Ome, Italy. Only experienced cardiac sur-
eons (more than 300 CABG procedures performed/year)
nd interventional cardiologists or radiologist (more than
50 CAS procedures performed as primary operator and
ore than 50 CAS in the last 2 years) were involved in the
tudy. The protocol was approved by the local institutional
thics committee, and all the patients provided written
nformed consent.
A team of physicians composed of neurologist, anesthe-
iologists, cardiac surgeons, and interventional physicians
as assembled. The neurologist was responsible for the
nitial evaluation and neurological follow-up of the patients.
n independent data and safety monitoring board of each
enter, not affiliated with the study investigators, reviewed
linical data to identify safety concerns. The monitoring
oard in each center was also responsible for selecting all
atients with eligible criteria to be included in the registry.
atients. Patients were eligible if they were 18 years of age
r older, had concomitant critical carotid and coronary
isease with coronary arteries impossible to revascularize
ercutaneously, and were suitable for CABG. All patients
ad a surgical risk expressed as Standard European system
or cardiac operative risk evaluation score (EuroSCORE)
5 (17,18), a carotid artery stenosis 50% in the symp-
omatic disease or 80% in asymptomatic disease, as
etermined by the NASCET (North American Symptom-
tic Carotid Endarterectomy Trial) criteria (19). The pres-
nce of carotid artery stenosis was evidenced by echocardi-
graphy duplex scanning, then confirmed by catheter
ngiography and either magnetic resonance angiography or
omputed tomography (CT) scan angiography. A CT scan
ith or without angiographic dye, depending on preproce-
ural serum levels of creatinine, was performed in all
atients to provide the maximum information regarding the
ortic arch, the extent of aortic disease, and the brain (Fig.
). In case of bilateral carotid artery stenosis, the choice of
he carotid artery to treat was made according to clinical
riteria or to the severity and morphology of plaque in case
f asymptomatic patients.
Exclusion criteria were: coagulopathy; intolerance to hep-
rin, aspirin, ticlopidine, or clopidogrel; ischemic stroke
ithin the previous 6 weeks; presence of intraluminal
arotid artery thrombus; peripheral vascular disease preclud-
ng use of catheter-based techniques; intracranial aneurismore than 9 mm in diameter; concomitant aortic and valve
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395isease or hemodynamically significant valvular heart dis-
ase; life expectancy of 1 year; or pregnancy.
linical evaluation. Exertional angina was classified accord-
ng to the Canadian Cardiovascular Society classification
20). Patients were classified as having unstable angina
ccording to Brauwald’s criteria (21). Patients were classi-
ed as having had an AMI if they had definite electrocar-
iographic changes and documentation of abnormal cardiac
nzyme levels (22). Patients were classified as having had a
troke according to the World Health Organization Task
orce on Stroke and other Cerebrovascular Disorders (23).
AS and CABG. The CAS procedures were performed under
ocal anesthesia through a percutaneous transfemoral access
ith the use of stents and protection devices approved by
he Accreditation Committee. An introducer sheath was
Figure 1. Multidetector CT Scan of Epiaortich Vessels
An electrocardiographic, gated, 64-multidetector computed tomography (CT) s
aortic arch, the amount of calcium, epiaortich vessels, and intracranial circulati
nial circulation. (C, D) Both carotid arteries are involved in critical ulcerated steositioned in the femoral artery, and heparin (1 mg/kg) was administered intra-arterially as a bolus. Then a guiding
atheter was placed in the common carotid artery, proxi-
ally to the bifurcation. A distal filter protection was used
n all patients. If needed, the lesion was pre-dilated after the
lacement of the protection device. After deployment,
tents were post-dilated to achieve a residual stenosis30%.
uring and after CAS pressure monitoring was obtained to
revent hyperpefusion syndrome. At the end of the proce-
ure, patients were transferred directly to the operating
oom for CABG. Surgeons performed CABG procedure
ccording to standard practice. All CABG were performed
n normothermic cardiopulmonary bypass with warm blood
ardioplegia as myocardial cardioplegic protection.
eriprocedural pharmacological protocol. Aspirin 100 mg
nce daily was started at least 3 days before CAS and daily
performed to provide the maximum anatomical information regarding the
) A CT volume rendering shows a type III aortic arch. (B) Anatomical intracra-can is
on. (After combined procedure was performed. As previously
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396entioned, heparin was administered 1 mg/kg as a bolus
ntra-arterially immediately before the stent implantation
rocedure and in the operating room before the cardiopul-
onary bypass 2 mg/kg as a bolus. Activated clotting time
ACT) was checked every 30 min and was constantly
aintained 250 s until the CABG procedure and 480 s
ntil the end of the cardiopulmonary bypass. Tranexamic
cid (TXA) 2 g in bolus was administered as an antifibrino-
ytic agent over 20 min before sternotomy and then as
ndovenous infusion (0.5 g/h) until the patient was admit-
ed to the post-operative intensive care unit. Clopidogrel,
00 mg as a loading dose, followed by 75 mg/day for 1
onth was started in the intensive care unit via a nasogastric
ube 6 h after the end of CABG surgery, providing that
urgical bleeding from the thoracic drains had either defi-
itely stopped, or when it was 50 ml/h for 3 consecutive
ours from the sixth post-operative hour on.
ollow-up and end points. Neurological evaluation, includ-
ng assessment according to the National Institutes of
ealth Stroke Scale, the Barthel Index of functional levels
n activities of daily living, the Rankin scale of functional
isability and monitoring for adverse clinical events, was
erformed within 24 h after the procedures, daily thereafter
ntil hospital discharge, and at 6- and 12-month follow-up
isits by a neurologist (24–26).
A computerized tomographic brain scan was performed
efore discharge from the hospital and compared with the
re-operative CT scan. Color duplex ultrasonography eval-
ation was repeated before hospital discharge and at the 6-
nd 12-month follow-up.
The primary end point was the combined incidence of
troke, AMI, or death within 30 days after the treatment.
econdary outcomes were the incidence AMI, TIA, major
ocal complications, bleeding and systemic complications
ithin 30 days after the treatment and the combined incidence
f stroke, AMI, or death from the 31st day to 12 months of the
ollow-up. The occurrence of stroke, AMI, death, and other
linical events was assessed by an independent safety monitor-
ng board that reviewed the data periodically.
ata collection and statistical analysis. Clinical and proce-
ural data were updated on a specific website to be analyzed by
he data coordinating center (Division of Cardiac Surgery, Tor
ergata University of Rome). The investigators had full access
o all data. Carotid and intracranial arteries angiography was
erformed before CAS, and the results were analyzed with the
se of a computerized system. The study design, all analysis,
nd the decision to publish were determined solely by the
rincipal investigator and the study investigators. The analysis
f immediate, 30-day, and 12-month outcomes was possible
or all the patients included in the registry. Continuous
ariables were tested for normal distribution with the
olmogorov-Smirnov 1-sample test. Those variables with a
ormal distribution were expressed as mean  SD. Variables
ith a skewed distribution were logarithmically transformedor statistical analysis and were expressed as medians and
nterquartile range. Categorical variables were expressed as
roportion and percentages. Statistical analysis was performed
ccording to “intention to treat” analysis. Kaplan-Meier sur-
ival analysis was used to analyze event-free survival.
The SAS software (version 8.2, SAS Institute, Inc., Cary,
orth Carolina) was used for all the analyses. The authors
ouch for the completeness and veracity of data and data
nalyses.
esults
atients and treatment. Between February 2006 and March
007, 101 high-risk consecutive patients with severe carotid
rtery disease and CAD were enrolled in the study. At the
ime the procedures were performed, 26 patients (26%) had
nstable angina, 41 (41%) had exertional angina class
II/IV, and 16 (16%) had had a previous cerebrovascular
ccident. Fifty-six patients (55%) had significant bilateral
arotid artery stenosis, 79 (78%) had 3-vessel CAD, and 41
41%) had left main stem involvement. The mean Standard
uroSCORE was 8.6  2.5. Other baseline clinical char-
cteristics of the patients are reported in Table 1.
Table 1. Baseline Characteristics of the Patients (n  101)
Age, yrs 69.2 8.1
Male sex 86 (85)
Exertional angina class III/IV* 41 (41)
Unstable angina 26 (26)
Diabetes 51 (50)
Chronic renal failure† 15 (15)
Bilateral carotid stenosis 56 (55)
Patients with symptomatic carotid stenosis 15 (15)
Percent carotid stenosis in symptomatic patients 79.4 9.1
Percent carotid stenosis in asymptomatic patients 80.5 8.2
Bilateral carotid stenosis 56 (55)
Type III aortic arch‡ 8 (8)
CT Agatston score§, median (range) 205 (80–325)
3-vessel disease 79 (78)
Left main involvement 41 (41)
Previous AMI 5 (5)
LVEF 51.7 11.2
Surgical risk 8.6 2.5
Values are expressed asmean n (%) ormean SD except where indicated otherwise. *According
to the classification system of the Canadian Cardiovascular Society (CCS). †Serum creatinine
concentration exceeding 2 mg/dl and creatinine clearance rate of 50. ml/min. ‡According to
the classification of aortic arches for carotid access (reprinted, with permission, from Myla S.
Carotid techniques: an algorithmic approach. In: HenryM,Ohki T, PolydorouA, Strigaris K, Kiskinis
D, editors. Angioplasty and Stenting of the Carotid and Supra-aortic Trunks. United Kingdom:
Taylor & Francis Group, 2004:291–300). §Atherosclerotic burden measurement (reprinted, with
permission, from Agatston AS, Janowitz WR, Holdner FJ, Zusmer NR, Viamonte M Jr., Detrano R.
Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol
1990;15:827–32). Surgical risk expressed as EuroSCORE (Eur J Cardiothor Surg 1999;15:816–23).
AMI  acute myocardial infarction; CT  computed tomography; LVEF  left ventricularejection fraction.
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397In 77 of the 101 patients (76%), the loading dose of
lopidogrel was administered 6 h after the end of CABG
nd, in the remaining 24 patients (24%), 10 h after CABG.
rocedural data are reported in Table 2.
nd points. The rate of procedural success was 98%, and the
0-day cumulative incidence of disabling stroke, AMI, or
eath was 4%. Two patients (2%) with severe bilateral
arotid artery disease had a stroke immediately after carotid
rtery stent implantation, with a transient aphasia associated
ith mild hemiparesis in 1 patient and with paralysis of the
eft arm in the other patient. In these cases the cardiac
urgical procedure was delayed for 2 months, after a partial
unctional neurological recovery was achieved. One other
atient had a brief and transient post-stenting cerebral
schemia that was completely resolved by the end of the
tenting procedure. This patient underwent neurological
valuation and CT scan to rule out hemorrhage before
nducing general anesthesia for the planned surgical
rocedure.
Two patients (2%) with a standard EuroSCORE8 died
f multiple-organ failure approximately 30 days after
ABG (Table 3).
The 12-month cumulative incidence of stroke, AMI, or
eath was 7% (95% confidence interval: 0.91 to 0.99) (Fig.
). Secondary outcomes are reported in Table 3. In partic-
lar, 3 patients had post-operative bleeding requiring rein-
ervention, and 1 patient had pericardial tamponade requir-
ng pericardial drainage 4 days after CABG. Three patients
ied from the 31th day to 12 months after the procedures.
The median duration of post-operative hospital stay was
Table 3. Clinical Outcomes Within 30 Days After Hybrid Revascularization
(n  101)
Nonfatal stroke 2 (2)
TIA 1 (1)
Death 2 (2)
Fatal stroke 0
AMI* 0
Other cause 0
Any stroke, AMI*, or death 4 (4)
Major local complications
Hematoma 0
Femoral pseudoaneurysm at puncture site 1 (1)
Thrombosis at puncture site 1 (1)
Major bleeding 4 (4)
Renal failure† 1 (1)
Values are expressed asmeann (%). *Acutemyocardial infarction (AMI) definedby at least 2 of the
following criteria: typical chest pain lasting 20 min or more; serum levels of creatine kinase,
creatine kinase-MB, or troponin at least twice the upper limit of the normal range; and new
Q-wave on at least 2 adjacent derivations. †Acute renal failure after intervention (serum creati-
nine 1.5 mg/dl) or impairment of pre-existing chronic renal failure (basal value of serum
creatinine 0.5 mg/dl for 2 consecutive days).
TIA transient ischemic attack.Table 2. Characteristics of Treatment and In-Hospital Stay (n  101)
Stenting
Mean length of lesion (mm) 15.2 6.4
Predilation of stenosis 25 (25)
Duration of procedure (min)
Median 27
Interquartile range 14–92
Volume of angiographic dye administered (ml) 42 19
Type of stent used
Carotid Wallstent (Boston Scientiﬁc) 62 (61)
Acculink (Abbott) 17 (17)
X-ACT(Abbott) 12 (12)
Vivexx (Bard Peripheral Vascular) 6 (6)
Cristallo (Invatec) 4 (4)
Cerebral protection used
FilterWire EZ (Boston Scientiﬁc) 39 (39)
Spider (ev3) 5 (5)
EPI FilterWire (Boston Scientiﬁc) 46 (46)
Accunet (Abbott) 11 (11)
CABG intervention
Duration of extracorporeal circulation (min)
Median 78
Interquartile range 66–103
Clamping time (min)
Median 47
Interquartile range 35.5–59.8
Number of graft 3.0 0.7
LIMA  RIMA 18 (18)
Ventilation time (h)
Median 12
Interquartile range 7.2–13.8
Transfusions (U)
Median 0
Interquartile range 0–2
Number of red blood cell transfused patients 18 (18)
Number of patients who received more than 2 blood units 1 (1)
Tube drainage
At 24 h
Median 310
Interquartile range 60–1,000
Total
Median 450
Interquartile range 100–1,150
Intensive care stay (days)
Median 2
Interquartile range 2–3
Post-operative length of stay (days)
Median 9
Interquartile range 7–14
Values are expressed as mean n (%) or mean SD except where indicated otherwise.
CABG  coronary artery bypass graft; LIMA  left internal mammary artery; RIMA  rightdays (interquartile range, 7 to 14 days). The median
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398uration of intensive care unit stay was 2 days (interquartile
ange, 2 to 3 days), and the median ventilation time was
2 h (interquartile range, 7.3 to 13.8 h). The incidence of
rimary outcome events at 12 months is summarized in
able 4.
iscussion
eurological complications of varying severity unfortunately
re relatively common after CABG, in particular in a certain
igh-risk group of patients. Extracranial carotid artery
isease is significantly associated with a type I adverse
eurological outcome (i.e., death due to stroke or hypoxic
ncephalopathy, nonfatal stroke, TIA, stupor, or coma at
he time of discharge) (27). Hemodynamically significant
arotid artery stenoses are associated with as many as 30% of
arly post-operative CABG strokes (28). These complica-
ions can have important clinical and psychological effects
n the affected patients. Roach et al. (27) showed that
dverse neurological events occurred in 6.1% of patients,
early one-half of whom (3.1%) had severe complications
ncluding stroke and coma. In those who had complication
fter CABG, the mortality rate was very high (21%).
reventing stroke and cardiovascular events after CABG is
n important and complex problem. The trend to perform
oronary surgery in an increasingly elderly population un-
erscores the importance of the issue (29,30). Concomitant
arotid artery disease might be a major factor contributing
o the occurrence of post-operative stroke (31,32). Other
actors, however, might be equally important. Carotid artery
isease might be a marker of diffuse atherosclerosis, affect-
Figure 2. Actuarial Event-Free Survival at 12 Months
Kaplan-Meier event-free survival in patients that underwent simultaneous
hybrid revascularization by carotid artery stenting and coronary artery
bypass graft surgery. The 12-month cumulative incidence of disabling
stroke, acute myocardial infarction, or death was 7%. Three patients died
between the 31st day and 12 months after intervention.ng also aortic arch, arch vessels, and intracranial vessels.he presence of generalized atherosclerosis might increase
he occurrence of hemorrhage, watershed ischemia, or
mboli, all of which might result in a stroke. Otherwise,
oncomitant significant CAD increases the mortality
mong patients undergoing CEA (2,3). In patients with
uch a disease, a simplified operative management like
ybrid revascularization by CAS and CABG can minimize
he negative impact of diffuse atherosclerotic disease. In
act, our findings indicate that, in symptomatic patients
ith combined carotid artery disease and CAD at high
urgical risk, the approach that we proposed is a feasible
herapeutic option with good immediate and mid-term
linical results.
Recently, a series published by a single institution in the
ast 7 years has shown that in 1,769 patients undergoing
ombined procedures the incidence of stroke and TIA
verages 3.8%, AMI averages 3.1%, and mortality averages
.5% (11). Recently, Hertze and Mascha (33) confirmed
hese results, reporting a post-operative stroke and operative
ortality rate of 10.3% for simultaneous CEA and CABG
urgical interventions. According to these results, in a
revious series of 180 consecutive patients undergoing
ombined surgical revascularization at the Tor Vergata
niversity of Rome between 1991 and 2002, the 30-day
ortality and stroke rate was 10% and 1.1%, respectively
34), with a mortality rate of 14.5% when the standard
uroSCORE was 6 or more and 3.4% when it was lower
han 5. These high-risk patients could be treated by an
lternative strategy such as the hybrid approach proposed in
his study.
In fact, in a recent study, we demonstrated a reduction of
he mortality rate to 5.4% when the hybrid approach was
sed in high-risk patients (16). Remarkably, 14% of these
atients treated with CAS and CABG also underwent valve
urgery repair.
As compared with combined surgical revascularization,
he hybrid strategy requires a shorter surgical time and less
xtensive surgical trauma, thus reducing cofactors known to
ncrease morbidity and mortality. A recent meta-analysis
emonstrated a superiority of CEA as compared with CAS
egarding the evaluation of death and stroke at 30 days (35).
Table 4. Incidence of Clinical Events at 12 Months (n  101)
Any stroke, AMI, or death at 30 days* 4 (4)
Any stroke, AMI, or death between 31 days and 12 months 3 (3)
Stroke 0
Death 3 (3)
AMI 0
Any stroke, AMI, or death within 12 months 7 (7)
Values are expressed as mean n (%). *Any stroke or death included a stroke in 2 patients
immediately after carotid artery stenting implantation, the planned coronary artery bypass graft-
ing was delayed 2 months later after neurological recovery.AMI acute myocardial infarction.
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399owever, this superiority is not evident if combined hard
nd point analysis such as death, stroke, and myocardial
nfarction are considered (34). As compared with CEA,
AS has uncertain efficacy and safety in patients at risk for
troke for atherosclerotic stenosis of the internal carotid
rtery (36). In particular in high-risk patients for CEA,
ainly due to severe CAD, the SAPPHIRE (Stenting and
ngioplasty with Protection in Patients at High Risk for
ndarterectomy) trial showed that CAS was safer than
EA, because it had a lower postprocedure risk of AMI at
0 days as compared with surgery (13). This is likely to be
he case mainly in patients with elevated surgical risk, such
s the patients involved in the SHARP (Study of Heart and
enal Protection) study. In fact, according to our inclusion
riteria, we enrolled only patients with a standard Euro-
CORE equal to or above 5, with an elevated surgical
ortality. In particular, when the standard EuroSCORE is
, as it is in our study, the surgical mortality rate might be
s high as 14.5% (18,37,38). In this high-risk subset of
atients, specific surgical complications are also elevated:
ukuda et al. (37) reported a morbidity rate of 56.5%. In
articular, when both internal carotid arteries have signifi-
ant stenosis, the risk of stroke after cardiac surgery is
articularly high: 25%, as reported by Tunio et al. (38). On
he contrary, with the percutaneous hybrid approach as in
ur study, the stroke rate was only 2% (2 patients), consid-
ring that 55% of our patients had bilateral internal carotid
rtery disease. Such results might also be due to the fact that
ur study involved only high-volume centers and all the
rocedures were performed by experienced operators.
In particular, the invasive cardiologist or radiologist
nvolved in the study performed more than 150 CAS as
rimary operator, according to the consensus document on
arotid stenting procedures (39).
Another potential advantage of the simultaneous hy-
rid approach as compared with a combined surgical
pproach is that during the CAS procedure the patient is
wake and the neurological outcome will be known
nstantly rather than after the patient emerges from
eneral anesthesia. However, our strategy might have
ome additional advantages as compared with staged
EA- or CAS-CABG, because it seems to reduce the
isk of AMI during CEA (13) or in the time elapsing
etween the 2 procedures, because this interval is virtually
liminated (40). In fact, the AMI rate in the time the
atient is waiting for CABG after carotid artery proce-
ure was 4.4% and 5.8%, respectively, when CEA- and
AS-CABG was performed (11,38). Finally, we re-
orted the same intensive care and hospital stay, com-
ared with our low-risk patients, despite the elevated risk
f morbidity of patients enrolled. This fact is very
mportant also for economic reasons, because costs are
educed in the high-risk subset of patients, as in those
ith high EuroSCORE (41). sNormothermic cardiopulmonary bypass has been used in
ur patients. Although hypothermia might be safer from a
eurological point of view (42), it carries a higher risk of
leeding, due to platelet dysfunction, in patients that should
ndergo aggressive antiplatelet aggregation treatment after
AS (43).
It is likely that off-pump techniques might further reduce
he overall stroke risk, especially in patients with aortic wall
isease.
Nonetheless, our study also demonstrated safety of the
eriprocedural pharmacological protocol and the timing of
ntiplatelet administration proposed: in fact, the bleeding
ate after surgical intervention was low. Only 1 patient had
ericardial tamponade requiring pericardiocentesis, and 3
atients had bleeding after surgery requiring reintervention.
n all patients the need for post-operative blood transfusions
as not different from those who underwent conventional
reatment where antiplatelet aggregation therapy was
topped before CABG (44).
Moreover, no cardiovascular event, stroke, or TIA oc-
urred from hospital discharge to the first 30-days of the
ollow-up.
Therefore, in patients with combined carotid artery
isease and CAD at high surgical risk, the proposed hybrid
pproach seems to be a possible alternative therapeutic
trategy.
tudy limitations. This study has a certain number of
imitations. It was not a randomized trial comparing hybrid
pproach (CAS and CABG) versus an all surgical approach
CEA and CABG). The patient population is not very
arge, although composed of carefully selected individuals
oming from 4 high-volume centers. Indeed, at the present
ime a larger number of patients with multivessel CAD are
reated percutaneously, with drug-eluting stents in particu-
ar, when at high surgical risk.
The use of angiographic dye during the CAS procedure
ight be the major drawback of this approach, in particular
n high-risk patients with chronic renal failure. In our study
nly 1 patient with chronic renal failure had transient renal
mpairment after the procedure. Particular attention was
ade to reduce the amount of angiographic dye (i.e., a
road-mapping” X-ray acquisition was used during the stent
mplantation, and in patients with chronic renal failure, a
re-treatment with fluid administration and acetilcysteine
as made) (45).
onclusions
ven if a randomized clinical study is needed to verify our
linical approach, our findings indicate that, in high-risk
atients with CAD suitable for CABG and carotid artery
isease, hybrid revascularization by CAS immediately fol-
owed by CABG is a feasible and promising therapeutic
trategy.
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